VivoSeq
Metabolic & Endocrine

Polycystic Ovarian Syndrome (PCOS)

1

Pipeline Programs

3

Active Trials

4

Companies Involved

Polycystic Ovarian Syndrome (PCOS) is an early-stage landscape with 1 program across 4 companies. The most active players are AstraZeneca, Merck & Co., Ferring.

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Preclinical
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Trial Status

11

clinical trials

Completed7 · 64%
Recruiting3 · 27%
Unknown status1 · 9%

Trial Activity

11 trials

Vitamin D and Polycystic Ovarian Syndrome (PCOS)
Recruiting··Phase 2·NCT03989778·300 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)